Non-antigen-specific and antigen-specific immune therapies for chronic hepatitis B: evidences from laboratory benches and patient's bedsides

Abstract

Introduction: Due to unsatisfactory therapeutic efficacy and considerable side effects of antiviral drugs in patients with chronic hepatitis B (CHB), immunotherapy has emerged as an alternative approach. CHB immunotherapy may be categorized into two main types: i) non-antigen-specific immune therapy and ii) hepatitis B virus (HBV) antigen-specific immune therapy. Although different immune modulators have been used in CHB patients for the last two to three decades, the nature and design of ongoing regimens of immunotherapeutic approaches need considerable modifications.

Areas covered: In this review, the authors have outlined the relevant immunotherapies for CHB patients that have been used for the last two to three decades. The mechanisms underlying the limited therapeutic efficacy of available therapeutic agents for CHB patients have been discussed to aid in the development of an effective therapeutic approach for these patients.

Expert opinion: Circumstantial evidence indicates that a better regimen of immunotherapy may be developed using different HBV-related antigens or combinations of two or more HBV-related antigens, or combinations of HBV-related antigens and antiviral drugs. However, the capacity of ‘inducible immunity' by immune modulators to cure or block progression of liver diseases in CHB patients needs to be addressed.

Keywords::

• antigen-specific immune modulators
• chronic hepatitis B
• immune therapy
• inducible immunity
• non-antigen-specific immune modulators
• therapeutic vaccine

Acknowledgement

The authors would like to acknowledge American Eagle Editing Office, USA.

Notes

This box summarizes key points contained in the article.